335 related articles for article (PubMed ID: 15293073)
1. Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly.
Ruf BR; Colberg K; Frick M; Preusche A
Infection; 2004 Aug; 32(4):191-8. PubMed ID: 15293073
[TBL] [Abstract][Full Text] [Related]
2. Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly.
de Bruijn I; Meyer I; Gerez L; Nauta J; Giezeman K; Palache B
Vaccine; 2007 Dec; 26(1):119-27. PubMed ID: 18063446
[TBL] [Abstract][Full Text] [Related]
3. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant.
Vesikari T; Pellegrini M; Karvonen A; Groth N; Borkowski A; O'Hagan DT; Podda A
Pediatr Infect Dis J; 2009 Jul; 28(7):563-71. PubMed ID: 19561422
[TBL] [Abstract][Full Text] [Related]
4. [Study on the safety and immunogenicity of MF59-adjuvanted influenza subunit vaccine in Chinese elderly].
Li RC; Fang HH; Li YP; Liu YP; Nong Y; Huang GB
Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Jun; 29(6):548-51. PubMed ID: 19040034
[TBL] [Abstract][Full Text] [Related]
5. MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications.
Baldo V; Baldovin T; Floreani A; Carraro AM; Trivello R;
Vaccine; 2007 May; 25(20):3955-61. PubMed ID: 17383057
[TBL] [Abstract][Full Text] [Related]
6. Influenza vaccine with squalene adjuvant: new preparation. No better than available products.
Prescrire Int; 2004 Dec; 13(74):206-8. PubMed ID: 15599987
[TBL] [Abstract][Full Text] [Related]
7. Clinical experience with inactivated, virosomal influenza vaccine.
de Bruijn IA; Nauta J; Cramer WC; Gerez L; Palache AM
Vaccine; 2005 Jul; 23 Suppl 1():S39-49. PubMed ID: 16005120
[TBL] [Abstract][Full Text] [Related]
8. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination.
Vesikari T; Groth N; Karvonen A; Borkowski A; Pellegrini M
Vaccine; 2009 Oct; 27(45):6291-5. PubMed ID: 19840662
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and tolerability of a virosome influenza vaccine compared to split influenza vaccine in patients with sickle cell anemia.
Souza AR; Braga JA; de Paiva TM; Loggetto SR; Azevedo RS; Weckx LY
Vaccine; 2010 Jan; 28(4):1117-20. PubMed ID: 20116631
[TBL] [Abstract][Full Text] [Related]
10. An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine.
Del Giudice G; Hilbert AK; Bugarini R; Minutello A; Popova O; Toneatto D; Schoendorf I; Borkowski A; Rappuoli R; Podda A
Vaccine; 2006 Apr; 24(16):3063-5. PubMed ID: 16464520
[TBL] [Abstract][Full Text] [Related]
11. Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus.
Zuccotti GV; Scaramuzza A; Riboni S; Mameli C; Pariani E; Tanzi E; Zanetti A; Radaelli G
Vaccine; 2009 Aug; 27(39):5357-62. PubMed ID: 19607951
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations.
Atmar RL; Keitel WA; Patel SM; Katz JM; She D; El Sahly H; Pompey J; Cate TR; Couch RB
Clin Infect Dis; 2006 Nov; 43(9):1135-42. PubMed ID: 17029131
[TBL] [Abstract][Full Text] [Related]
13. Comparison between a conventional subunit vaccine and the MF59-adjuvanted subunit influenza vaccine in the elderly: an evaluation of the safety, tolerability and immunogenicity.
Sindoni D; La Fauci V; Squeri R; Cannavò G; Bacilieri S; Panatto D; Gasparini R; Amicizia D
J Prev Med Hyg; 2009 Jun; 50(2):121-6. PubMed ID: 20099444
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence.
Vesikari T; Karvonen A; Tilman S; Borkowski A; Montomoli E; Banzhoff A; Clemens R
Pediatrics; 2010 Oct; 126(4):e762-70. PubMed ID: 20819892
[TBL] [Abstract][Full Text] [Related]
15. [Comparative study on safety and immunogenicity between influenza subunit vaccine and split vaccine].
Dong PM; Li YQ; Zheng TZ; Jia YP; Li F; Han TW; Qiao RX; Zhang BH
Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Jul; 24(7):570-3. PubMed ID: 12975010
[TBL] [Abstract][Full Text] [Related]
16. The virosomal influenza vaccine Invivac: immunogenicity and tolerability compared to an adjuvanted influenza vaccine (Fluad in elderly subjects.
de Bruijn IA; Nauta J; Gerez L; Palache AM
Vaccine; 2006 Nov; 24(44-46):6629-31. PubMed ID: 16901593
[TBL] [Abstract][Full Text] [Related]
17. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
[TBL] [Abstract][Full Text] [Related]
18. A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects.
Hatz C; von Sonnenburg F; Casula D; Lattanzi M; Leroux-Roels G
Vaccine; 2012 May; 30(23):3470-7. PubMed ID: 22446638
[TBL] [Abstract][Full Text] [Related]
19. Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults.
Lopez P; Caicedo Y; Sierra A; Tilman S; Banzhoff A; Clemens R
J Infect Dis; 2011 Jun; 203(12):1719-28. PubMed ID: 21606530
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the immunogenicity and safety of the conventional subunit, MF59-adjuvanted, and intradermal influenza vaccines in the elderly.
Seo YB; Choi WS; Lee J; Song JY; Cheong HJ; Kim WJ
Clin Vaccine Immunol; 2014 Jul; 21(7):989-96. PubMed ID: 24828092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
